Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma

To determine the efficiency of topical cyclosporine-A (CSA) combined with mitomycin C (MMC) as an adjunctive treatment in diffuse conjunctival and corneal squamous cell carcinoma (CCSC).

Interventional case reports.

Two patients who had positive margins following surgical excision of CCSC were treated by topical CSA (0.05%) four times a day for 12 weeks, and topical MMC (0.01%) four times a day was combined with CSA at the second, fourth, and sixth weeks of the treatment. We controlled the tumor recurrence, vision, and ocular surface healing during the follow-up.

There was no tumor recurrence during the follow up of 18 months. Limbal vascularization regressed considerably and the vision improved without any ocular surface problems in both patients.

As an adjunctive treatment, topical CSA (0.05%) combined with MMC (0.01%), may prevent tumor recurrence and provide excellent ocular surface healing in diffuse CCSC.